Chemoinformaics analysis of gypenoside lxxvi
| Molecular Weight | 638.883 | nRot | 8 |
| Heavy Atom Molecular Weight | 576.387 | nRig | 27 |
| Exact Molecular Weight | 638.439 | nRing | 5 |
| Solubility: LogS | -4.086 | nHRing | 1 |
| Solubility: LogP | 3.327 | No. of Aliphatic Rings | 5 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 4 |
| Atoms Count | 107 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 45 | No. of Aromatic Carbocycles | 0 |
| nHetero | 9 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 4 |
| No. of Hydrogen atom | 62 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 36 | No. of Saturated Rings | 5 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 9 | No. of Arom Bond | 0 |
| nHA | 9 | APOL | 108.679 |
| nHD | 7 | BPOL | 65.6708 |
| QED | 0.198 |
| Synth | 5.592 |
| Natural Product Likeliness | 2.846 |
| NR-PPAR-gamma | 0.105 |
| Lipinski | Rejected |
| Pfizer | Accepted |
| GSK | Rejected |
| Golden Triangle | Rejected |
| Pgp-inh | 0.937 |
| Pgp-sub | 0.022 |
| HIA | 0.874 |
| CACO-2 | -5.065 |
| MDCK | 0.0000131 |
| BBB | 0.014 |
| PPB | 0.943757 |
| VDSS | 0.892 |
| FU | 0.0477933 |
| CYP1A2-inh | 0.002 |
| CYP1A2-sub | 0.115 |
| CYP2c19-inh | 0.002 |
| CYP2c19-sub | 0.775 |
| CYP2c9-inh | 0.007 |
| CYP2c9-sub | 0.056 |
| CYP2d6-inh | 0.002 |
| CYP2d6-sub | 0.094 |
| CYP3a4-inh | 0.071 |
| CYP3a4-sub | 0.073 |
| CL | 3.105 |
| T12 | 0.087 |
| hERG | 0.058 |
| Ames | 0.036 |
| ROA | 0.094 |
| SkinSen | 0.101 |
| Carcinogencity | 0.009 |
| EI | 0.008 |
| Respiratory | 0.891 |
| NR-Aromatase | 0.641 |
| Antiviral | Yes |
| Prediction | 0.751167 |